---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Definition and etiology"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Definition and etiology. Topics: Blood pressure categories: 2025 AHA/ACC guideline, Treatment goal and controlled hypertension, Uncontrolled hypertension: definition in a US real-world prevalence study, Resistant hypertension definition: 2025 AHA/ACC guideline, and 12 further topics. 16 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Blood pressure categories: 2025 AHA/ACC guideline

> “Blood pressure is classified by the following framework: normal blood pressure is defined as <120 mm Hg systolic and <80 mm Hg diastolic; elevated blood pressure as 120 to 129 mm Hg systolic and <80 mm Hg diastolic; stage 1 hypertension as 130 to 139 mm Hg systolic or 80 to 89 mm Hg diastolic; and stage 2 hypertension as ≥140 mm Hg systolic or ≥90 mm Hg diastolic.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-2"></a>

### Treatment goal and controlled hypertension

> “The overarching blood pressure treatment goal is <130/80 mm Hg for all adults, with additional considerations for those who require institutional care, have a limited predicted lifespan, or are pregnant.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Controlled hypertension: Among those with hypertension, defined as having systolic blood pressure below 130 mm Hg and diastolic blood pressure below 80 mm Hg.”

Source: [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)

<a id="topic-2.2.1.1-3"></a>

### Uncontrolled hypertension: definition in a US real-world prevalence study

> “Hypertension (HTN) is classified as uncontrolled (uHTN) when systolic or diastolic blood pressure (BP) is greater than 130/80 mm Hg despite patients receiving anti-hypertensive treatments (AHTs).”
> “HTN is classified as resistant (rHTN) when it remains uncontrolled despite patients receiving at least 3 AHTs, or when it is controlled and patients receive at least 4 AHTs.”

Source: [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf)

<a id="topic-2.2.1.1-4"></a>

### Resistant hypertension definition: 2025 AHA/ACC guideline

> “Resistant hypertension is defined as BP above goal despite treatment with 3 antihypertensive medications with complementary mechanisms of action, including a diuretic at maximally tolerated doses or BP at goal but requiring ≥4 medications (Figure 8).”
> “Evaluation of resistant hypertension requires exclusion of pseudoresistance, including inaccurate BP measurement”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-5"></a>

### Controlled, uncontrolled, and apparent treatment-resistant hypertension: AHA scientific statement

> “RH is defined as the BP of a hypertensive patient that remains elevated above goal despite the concurrent use of 3 antihypertensive agents of different classes, commonly including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (angiotensin-converting enzyme [ACE] inhibitor or angiotensin receptor blocker [ARB]), and a diuretic.”
> “RH also includes patients whose BP achieves target values on ≥4 antihypertensive medications, a condition that has been referred to in the literature as controlled RH. Thus, the term RH refers to hypertension with both uncontrolled and controlled BP, depending on the number of antihypertensive agents used.”
> “The term apparent treatment RH (aTRH) is used when ≥1 of the following data elements are missing: medication dose, adherence, or out-of-office BP; thus, pseudoresistance cannot be excluded.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.1-6"></a>

### Resistant hypertension definition: European guidelines

> “Hypertension is defined as resistant when a treatment strategy including appropriate lifestyle measures and treatment with maximum or maximally tolerated doses of a diuretic (thiazide or thiazide-like), a RAS blocker, and a calcium channel blocker fail to lower office systolic and diastolic BP values to <140 mmHg and/or <90 mmHg, respectively.”
> “Resistant hypertension is not a disease, but an indicator that should be used to identify patients at high risk for CVD, in which secondary hypertension is also frequent;”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

> “In the 2018 Guidelines, hypertension was defined as resistant to treatment when appropriate lifestyle measures and treatment with optimal or best tolerated doses of three or more drugs (a Thiazide/Thiazide-like diuretic, an RAS blocker and a CCB) fail to lower office BP to <140/90 mmHg”
> “Evidence of adherence to therapy and exclusion of secondary causes of hypertension are required to define true resistant hypertension, otherwise resistant hypertension is only apparent and termed as pseudoresistant hypertension (Fig. 13).”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.1.1-7"></a>

### Etiology of primary hypertension: behavioral, environmental, hormonal, and genetic factors

> “Elevated BP and hypertension reflect a complex interplay of behavioral, environmental, hormonal, and genetic influences across the lifespan (Table 8).”
> “Among dietary factors influencing BP, higher sodium intake, lower potassium intake (measured by urinary excretion), and alcohol overuse predominate; low intake of fiber, calcium, magnesium, and plant protein also influence BP.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “The causes of hypertension are multifactorial, including genetics, environmental (e.g., air pollution), dietary influences (e.g., high sodium intake, alcohol), medical conditions (e.g., primary aldosteronism, obesity, sleep disordered breathing, or kidney, thyroid, or adrenal disease), and psychosocial stressors.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.1-8"></a>

### Risk factors and demographic correlates of resistant hypertension

> “Multiple cohort studies have identified common risk factors for resistant hypertension, including older age, obesity, CKD, and diabetes.”
> “Resistant hypertension is more common in Black populations, which may be related to adverse social factors, including living in a professional shortage area or disadvantaged neighborhood and clinical inertia.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

> “Demographic correlates of RH include black race, older age, and male sex.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.1-9"></a>

### Secondary hypertension: settings and common causes

> “Secondary hypertension is more common with stage 2 hypertension, treatment-resistant hypertension, sudden onset of hypertension, increased BP in patients with hypertension previously controlled on drug therapy, early-onset hypertension (age <30 years), diastolic hypertension in older adults, and target organ damage disproportionate to the duration or severity of the hypertension.”
> “Common forms of secondary hypertension include primary aldosteronism and obstructive sleep apnea (OSA).”
> “Secondary hypertension is more common among adults with resistant hypertension, particularly primary aldosteronism, OSA, renal parenchymal disease, and renovascular disease.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-10"></a>

### Interfering medications

> “Approximately 20% of adults with hypertension reported regular use of over-the-counter or nonprescription medications that may directly raise BP or interfere with antihypertensive drug efficacy, such as NSAIDs or nasal decongestants (Table 17).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-11"></a>

### Primary aldosteronism: definition and adrenal subtypes

> “Primary aldosteronism is defined as a group of disorders in which aldosterone production is inappropriately high for sodium and volume status, is relatively autonomous of the major regulators of aldosterone secretion (angiotensin II and potassium), and cannot be completely suppressed with sodium loading.”
> “In two-thirds of patients with primary aldosteronism, excess aldosterone is caused by bilateral adrenal hyperplasia.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-12"></a>

### Primary aldosteronism prevalence by hypertension severity: 2025 AHA/ACC guideline

> “Primary aldosteronism is a common cause of secondary hypertension (occurring in 5% to 10% of patients with hypertension and 20% of patients with resistant hypertension), and targeted treatment is associated with improved kidney and cardiovascular outcomes.”
> “The prevalence of primary aldosteronism is approximately 5% to 10% among individuals with stage 1 hypertension and 11% to 22% among individuals with stage 2 hypertension, which varies depending on the modality of testing and testing thresholds used to diagnose primary aldosteronism.”
> “The prevalence of primary aldosteronism may be similar among individuals with stage 2 hypertension and those with resistant hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.1-13"></a>

### Primary aldosteronism in resistant hypertension: cohort studies with confirmatory testing

> “Mean adjusted levels of urinary aldosterone were 6.5 μg/24 h (95% CI, 5.2 to 7.7 μg/24 h) in normotension, 7.3 μg/24 h (CI, 5.6 to 8.9 μg/24 h) in stage 1 hypertension, 9.5 μg/24 h (CI, 8.2 to 10.8 μg/24 h) in stage 2 hypertension, and 14.6 μg/24 h (CI, 12.9 to 16.2 μg/24 h) in resistant hypertension; corresponding adjusted prevalence estimates for biochemically overt primary aldosteronism were 11.3% (CI, 5.9% to 16.8%), 15.7% (CI, 8.6% to 22.9%), 21.6% (CI, 16.1% to 27.0%), and 22.0% (CI, 17.2% to 26.8%).”

Source: [Brown et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/)

> “Over 20 years, we studied 1616 patients with resistant hypertension.”
> “On the basis of salt suppression tests, 182 (11.3%) patients had primary hyperaldosteronism, and response to spironolactone treatment further confirmed this diagnosis. Hypokalaemia was seen only in 83 patients with primary hyperaldosteronism (45.6%).”

Source: [Douma et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18539224/)

> “In this prospective study of 88 consecutive patients referred to a university clinic for resistant hypertension, we determined the 24-hour urinary aldosterone excretion during high dietary salt ingestion, baseline plasma renin activity, and plasma aldosterone in all subjects.”
> “Eighteen subjects (20%) were confirmed to have primary hyperaldosteronism. The prevalence of hyperaldosteronism was similar in black and white subjects.”

Source: [Calhoun et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12468575/)

<a id="topic-2.2.1.1-14"></a>

### Primary aldosteronism in resistant hypertension: review estimates

> “Primary aldosteronism (PA) is the leading cause of secondary hypertension, affecting at least 10% of all hypertensive patients and up to 25% of those with treatment-resistant hypertension, and is associated with markedly increased cardiovascular, metabolic, and kidney morbidity due to the systemic effects of excess aldosterone.”

Source: [Owei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12885222/)

> “Primary aldosteronism, which is characterized by excessive production of aldosterone, is one of the most common causes of treatment-resistant hypertension; between 11-30% of people with treatment-resistant hypertension are estimated to have primary aldosteronism.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.1-15"></a>

### Aldosterone dysregulation in uncontrolled and resistant hypertension: company statement

> “Dysregulated aldosterone levels are a key factor in uHTN or rHTN in approximately 30% of patients.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.2.1.1-16"></a>

### Obstructive sleep apnea and renovascular disease in resistant hypertension

> “Very high proportions (60%−84%) of individuals with RH have sleep apnea.”
> “Hypertension accelerated or worsened by renal artery stenosis remains among the most common causes of RH, particularly in older age groups.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Atherosclerotic renovascular disease may be present in 14% to 40% of adults with hypertension; however, only a small fraction (0.1% to 5%) is considered to be hemodynamically significant to result in renovascular hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
